传染病领域的药品黑市：私营部门之外的机会？
Broken drug markets in infectious diseases: Opportunities outside the private sector?
机构信息
Division of Infectious Diseases, Department of Medicine, HealthPartners, Minneapolis, Minnesota, United States of America.
HealthPartners Institute, Minneapolis, Minnesota, United States of America.
出版信息
PLoS Negl Trop Dis. 2019 Apr 11;13(4):e0007190. doi: 10.1371/journal.pntd.0007190. eCollection 2019 Apr.
Abstract
A subset of anti-infective drugs are increasingly unavailable for patients in the United States due to pricing or withdrawal from the market. Timely market solutions are needed. We assert that solutions to ensure access to some essential anti-infective agents lie outside capital markets and that public-private partnerships may be the most viable solution.
摘要
由于定价或退出市场的原因，越来越多的抗感染药物在美国无法供患者使用。需要及时采取市场解决方案。我们断言，确保获得一些基本抗感染药物的解决方案不在资本市场范围内，公私合作伙伴关系可能是最可行的解决方案。
相似文献
1
Broken drug markets in infectious diseases: Opportunities outside the private sector?传染病领域的药品黑市：私营部门之外的机会？
PLoS Negl Trop Dis. 2019 Apr 11;13(4):e0007190. doi: 10.1371/journal.pntd.0007190. eCollection 2019 Apr.
2
Running short.快用完了。
Minn Med. 2011 Oct;94(10):8-10.
3
Prescription drug prices in the US.美国的处方药价格。
Med Lett Drugs Ther. 2017 May 22;59(1521):81-83.
4
How the US Food and Drug Administration can solve the prescription drug shortage problem.美国食品和药物管理局如何解决处方药短缺问题。
Am J Public Health. 2013 May;103(5):e10-4. doi: 10.2105/AJPH.2013.301239. Epub 2013 Mar 14.
5
Eliminating neglected diseases: impact of published paper.消除被忽视疾病：已发表论文的影响
Health Aff (Millwood). 2007 Sep-Oct;26(5):1509. doi: 10.1377/hlthaff.26.5.1509.
6
Compulsory licensing and access to drugs.强制许可和药品获取。
Eur J Health Econ. 2015 Jan;16(1):83-94. doi: 10.1007/s10198-013-0556-2. Epub 2014 Jan 10.
7
Pharmaceuticals and medical devices: FDA oversight.药品和医疗器械：美国食品药品监督管理局的监管
Issue Brief Health Policy Track Serv. 2009 Jan 5:1-28.
8
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.一项不完整的药方：特朗普总统解决高药价问题的计划。
JAMA. 2018 Jun 19;319(23):2373-2374. doi: 10.1001/jama.2018.7424.
9
Critical drug shortages: implications for emergency medicine.关键药物短缺：对急诊医学的影响。
Acad Emerg Med. 2014 Jun;21(6):704-11. doi: 10.1111/acem.12389.
10
Prioritising neglected diseases related to poverty.优先考虑与贫困相关的被忽视疾病。
BMJ. 2005 Jul 2;331(7507):12. doi: 10.1136/bmj.331.7507.12.
引用本文的文献
1
Antifungal drug price increases in the United States, 2000-2019.美国抗真菌药物价格上涨，2000-2019 年。
Mycoses. 2022 Sep;65(9):859-865. doi: 10.1111/myc.13486. Epub 2022 Jul 18.
2
Patients perspectives on drug shortages in six European hospital settings - a cross sectional study.患者视角下的六种欧洲医院环境中的药品短缺情况 - 一项横断面研究。
BMC Health Serv Res. 2021 Jul 12;21(1):689. doi: 10.1186/s12913-021-06721-9.
3
Antiparasitic Drugs in the United States-Two Roads to High Prices.美国的抗寄生虫药物——通往高价的两条途径。
Front Sociol. 2020 Oct 22;5:540478. doi: 10.3389/fsoc.2020.540478. eCollection 2020.
本文引用的文献
1
Value-Based Pricing for Drugs: Theme and Variations.基于价值的药品定价：主题与变奏
JAMA. 2018 Jun 5;319(21):2165-2166. doi: 10.1001/jama.2018.4871.
2
Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.美国非专利药的可负担性与可及性——从国外进口的案例：观察性研究
BMJ. 2018 Mar 19;360:k831. doi: 10.1136/bmj.k831.
3
Access to benznidazole for Chagas disease in the United States-Cautious optimism?在美国，治疗恰加斯病的苯硝唑可及性——谨慎的乐观态度？
PLoS Negl Trop Dis. 2017 Sep 14;11(9):e0005794. doi: 10.1371/journal.pntd.0005794. eCollection 2017 Sep.
4
Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.针对不合理的处方药价格——马里兰州的反价格欺诈法。
N Engl J Med. 2017 Jul 13;377(2):101-103. doi: 10.1056/NEJMp1704907. Epub 2017 Jun 7.
5
Essential Medicines in the United States--Why Access Is Diminishing.美国的基本药物——可及性为何日益降低
N Engl J Med. 2016 May 19;374(20):1904-7. doi: 10.1056/NEJMp1601559.
6
The disappearing arsenal of antiparasitic drugs.抗寄生虫药物的逐渐消失的药库。
N Engl J Med. 2000 Oct 26;343(17):1273-4. doi: 10.1056/NEJM200010263431718.
Zotero 插件